DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» RespireRx
RespireRx
Summary Analgesics Dec2019
Asset Detail Acct Base Currency Code : USD ALL KR2 and KR3 - KR2GALLKRS00 As of Date : 12/31/2018 Accounting Status : REVISED
Respirerx Pharmaceuticals Inc. (Exact Name of Registrant As Specified in Its Charter)
Galien Forum & Prix Galien
Drug & Device Pipeline News
Cardiol Therapeutics Inc. | CRDL-TSX Initiating Coverage
2020 December
INSIDE with a New Index
Name of Faculty Or Presenter Reported Financial Relationship Consultant/Independent Contractor: Biodelivery Sciences Inc., Pfizer, U.S
An Investor's Guide to Understanding Gene Therapy
Asset Detail Acct Base Currency Code : USD ALL KR2 and KR3 - KR2GALLKRS00 As of Date : 9/30/2018 Accounting Status : REVISED
CEO INVESTOR CONFERENCE February 13-14, 2017 • the Waldorf Astoria New York
Partnering in the Pharma World: BIO-Europe® and Industry Trends 2017 Update
Proxy Statement Is Also Available At
New ICH E6 to Place More Demands on Trials, but COVID-19 Could Help Ease Adjustments
Johnson & Johnson (JNJ)
Asset Detail Acct Base Currency Code : USD ALL KR2 and KR3 - KR2GALLKRS00 As of Date : 3/31/2021 Accounting Status : FINAL
Biocorrx Welcomes Four Experts to Expanded Scientific Advisory Board
Top View
A New Generation of Antidepressants: an Update on the Pharmaceutical
Respirerx Pharmaceuticals Inc. (Exact Name of Registrant As Specified in Its Charter)
2021 Special Meeting Proxy Statement
PPCO Twist System
2018 Medicines in Development for Neurological Disorders a Report on Disorders of the Brain, Spinal Cord and Nerves
2019 Medicines in Development for Mental Illnesses
Documento De Registro Universal De Oryzon Genomics, S.A
Biogen/Ionis's Spinraza Approved
Research and Development Spending and Technical Efficiency: Evidence from Biotechnology and Pharmaceutical Sector
Participating Company List
Participating Company List
Gene Therapy - Near-Term Revolution Or Continued Evolution? STRATEGIC ADVICE and FINANCING Part 1: Global Proprietary Data (Abbreviated Version) Ravi Mehrotra, Ph.D